Phase
Condition
Prostate Cancer
Prostate Cancer, Early, Recurrent
Prostate Disorders
Treatment
IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
Proton (prostate bed) to 70.2 CGE
Clinical Study ID
Ages > 18 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Prostate cancer treated primarily with open, laparoscopic or robotically assistedprostatectomy.
Maximum PSA value of 20 ng/ml.
Exclusion
Exclusion Criteria:
Evidence of distant metastasis (M1).
Prior systemic chemotherapy for any reason.
Previous irradiation to the pelvis that would compromise the ability to deliver theprescribed study treatment.
Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerativecolitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease notaffecting the rectum are allowed).
History of hip replacement.
Prior or concurrent cancer, other than non-melanomatous skin cancer, unless diseasefree for at least 5 years.
Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its useduring radiation.
Study Design
Connect with a study center
University of Florida Proton Therapy Institute
Jacksonville, Florida 32206
United StatesActive - Recruiting
Northwestern Medicine Chicago Proton Center
Warrenville, Illinois 60555
United StatesActive - Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia 22031
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.